Skip to content

Arrowhead Research ARWR Proceeds from the sale of future royalties

Discontinued — last reported Q4 '25

Proceeds from the sale of future royalties at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$61.05M
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$72.5M
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$0
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$0
Royalty Pharma logo
Royalty PharmaRPRX
$915.6M+10.3%
Royalty Pharma logo
Royalty PharmaRPRX
$3.77M+2,032%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept arwr:ProceedsFromSaleOfFutureRoyalties.

The official record: Arrowhead Research’s 10-K, filed November 25, 2025, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's proceeds from the sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's proceeds from the sale of future royalties?
Arrowhead Research (ARWR) reported proceeds from the sale of future royalties of $0 in Q3 2025.
What does proceeds from the sale of future royalties mean?
Cash received today in exchange for future royalty payments.
How do you interpret proceeds from the sale of future royalties?
Higher proceeds indicate immediate liquidity generation, though it signals a trade-off of future revenue potential.
How does proceeds from the sale of future royalties compare across companies?
Used by R&D-heavy biotech firms to bridge funding gaps without issuing new equity.